ストックスクリーナーアプリを入手
36.81
1.63%
-0.61
前日終値:
$37.42
開ける：
$38.37
24時間の取引高:
394.11K
Relative Volume:
0.84
時価総額：
$2.38B
収益：
$87.56M
当期純損益:
$-167.47M
株価収益率:
-15.73
EPS:
-2.34
ネットキャッシュフロー:
$-148.20M
1週間 パフォーマンス:
-0.19%
1か月 パフォーマンス:
-15.77%
6か月 パフォーマンス:
-24.18%
1年 パフォーマンス:
-4.81%
1日の値動き範囲:
$36.19
$38.90
1週間の範囲:
$36.19
$38.90
52週間の値動き範囲:
$29.24
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
36.81 | 2.38B | 87.56M | -167.47M | -148.20M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 - The Manila Times
Kymera Therapeutics (KYMR) Expected to Announce Earnings on Thursday - MarketBeat
Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line (KYMR) - Seeking Alpha
When the Price of (KYMR) Talks, People Listen - Stock Traders Daily
Getting In Cheap On Kymera Therapeutics, Inc. (NASDAQ:KYMR) Is Unlikely - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Kymera rises after presentation at the J.P. Morgan event - MSN
SG Americas Securities LLC Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Jennison Associates LLC Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) & Gene Biotherapeutics (OTCMKTS:CRXM) - Defense World
Financial Snapshot: Analyzing Kymera Therapeutics Inc (KYMR)’s Key Ratio Metrics - The Dwinnex
Long Term Trading Analysis for (KYMR) - Stock Traders Daily
SG Americas Securities LLC Cuts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Inside Kymera's Upcoming Biotech Presentations: Key Investor Events You Can't Miss - StockTitan
(KYMR) Technical Data - Stock Traders Daily
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Average PT from Brokerages - Defense World
Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $55.06 - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Earns "Overweight" Rating from Stephens - MarketBeat
Kymera announces expansion of KT-474 HS and AD phase 2 studies - MSN
Kymera Therapeutics soars as Sanofi expands phase 2 trials - MSN
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.3%Time to Sell? - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Provides Business Update and Preliminary Cash Balance for 2024 - Defense World
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? - MSN
Kymera Therapeutics describes IRAK-4 degraders - BioWorld Online
How the (KYMR) price action is used to our Advantage - Stock Traders Daily
JPMorgan Chase & Co. Acquires 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Provides Pipeline Objectives for 2025, Stock Gains - MSN
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutio - GuruFocus.com
Kymera stock surges on product pipeline update By Investing.com - Investing.com Canada
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.4% HigherHere's Why - MarketBeat
Kymera reports progress in immunology drug trials By Investing.com - Investing.com South Africa
Kymera Therapeutics Shares Surge Amid 2025 Strategy Unveil - TipRanks
Kymera reports progress in immunology drug trials - Investing.com India
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - The Manila Times
Kymera Unveils Ambitious 2025 Immunology Pipeline Plans with $850M Cash Runway - StockTitan
Analysts Set Expectations for KYMR FY2029 Earnings - Defense World
Stifel sustains Buy on Kymera stock amid TPD drug optimism By Investing.com - Investing.com UK
Equities Analysts Set Expectations for KYMR FY2029 Earnings - MarketBeat
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 - The Manila Times
Kymera Therapeutics to Present Strategic Roadmap at J.P. Morgan Healthcare Conference - StockTitan
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock - MarketBeat
(KYMR) Trading Report - Stock Traders Daily
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $53.88 Consensus Price Target from Brokerages - Defense World
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):